锐客网

  1. 首页 > 生活杂烩 > 健康 > >

精准医学|樊嘉：精准医学时代肝细胞癌的系统治疗｜专家视角( 六 )


陈政, 王捷. 基于循证指南和精准医学时代背景下肝癌诊疗的思考与总结［J］. 岭南现代临床外科, 2018, 18(6): 615-617.
［3］LU SC, GU WQ. Essentials of precision medicine in practice of surgical oncology for hepatobiliary tumors［J］. Chin J Hepatobiliary Surg, 2019, 25(1): 1-4. (in Chinese)
卢实春, 顾万清. 肝胆肿瘤外科治疗精准医学概要［J］. 中华肝胆外科杂志, 2019, 25(1): 1-4.
［4］SCHULZE K, NAULT JC, VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing［J］. J Hepatol, 2016, 65(5): 1031-1042.
［5］FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma［J］. Lancet, 2018, 391(10127): 1301-1314.
［6］GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma［J］. Cell, 2019, 179(5): 1240.
［7］European Association for the Study of the Liver.EASL clinical practice guidelines: Management of hepatocellular carcinoma［J］. J Hepatol, 2018, 69(1): 182-236.
［8］HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology, 2018, 67(1): 358-380.
［9］LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359: 378-390.
［10］SCHULZE K, IMBEAUD S, LETOUZ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets［J］. Nat Genet, 2015, 47(5): 505-511.
［11］GYAWALI B, PRASAD V. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC［J］. Nat Rev Clin Oncol, 2017, 14(11): 653-654.
［12］SAWEY ET, CHANRION M, CAI C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening［J］. Cancer Cell, 2011, 19(3): 347-358.
［13］VILGRAIN V, PEREIRA H, ASSENAT E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial［J］. Lancet Oncol, 2017, 18(12): 1624-1636.
［14］CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial［J］. Lancet Oncol, 2009, 10(1): 25-34.
［15］BRUIX J, RAOUL JL, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial［J］. J Hepatol,2012, 57(4): 821-829.
［16］MARRERO JA, KUDO M, VENOOK AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study［J］. J Hepatol, 2016, 65(6): 1140-1147.
【精准医学|樊嘉：精准医学时代肝细胞癌的系统治疗｜专家视角】［17］FINN RS, MERLE P, GRANITO A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial［J］. J Hepatol, 2018, 69(2): 353-358.
［18］KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial［J］. Lancet, 2018, 391(10126): 1163-1173.
［19］CAINAP C, QIN S, HUANG WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial［J］. J Clin Oncol, 2015, 33(2): 172-179.
［20］CHENG AL, KANG YK, LIN DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial［J］. J Clin Oncol, 2013, 31(32): 4067-4075.
［21］BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 389(10064): 56-66.

推荐阅读


上一篇：达卡巴嗪|达卡巴嗪的溶媒及输注时间

下一篇：哈尔滨市疾控中心|哈尔滨市疾控中心发布！在外就餐和手部卫生注意事项！